227 related articles for article (PubMed ID: 6958351)
1. The use of intermediate dose methotrexate in increased risk childhood acute lymphoblastic leukemia. A comparison of three versus six courses.
Green DM; Brecher ML; Blumenson LE; Grossi M; Freeman AI
Cancer; 1982 Dec; 50(12):2722-7. PubMed ID: 6958351
[TBL] [Abstract][Full Text] [Related]
2. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Pullen J; Boyett J; Shuster J; Crist W; Land V; Frankel L; Iyer R; Backstrom L; van Eys J; Harris M
J Clin Oncol; 1993 May; 11(5):839-49. PubMed ID: 8487048
[TBL] [Abstract][Full Text] [Related]
3. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a pediatric oncology group study.
Sullivan MP; Chen T; Dyment PG; Hvizdala E; Steuber CP
Blood; 1982 Oct; 60(4):948-58. PubMed ID: 6956376
[TBL] [Abstract][Full Text] [Related]
4. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
5. Comparison of central nervous system prophylaxis with cranial radiation and intrathecal methotrexate versus intrathecal methotrexate alone in acute lymphoblastic leukemia.
Muriel FS; Svarch E; Pavlovsky S; Eppinger-Helft M; Braier J; Vergara B; Garay G; Kvicala R; Divito JM; Failace R; Dibar E; Jimenez E
Blood; 1983 Aug; 62(2):241-50. PubMed ID: 6575836
[TBL] [Abstract][Full Text] [Related]
6. Intermediate dose methotrexate in childhood acute lymphoblastic leukemia resulting in decreased incidence of testicular relapse.
Brecher ML; Weinberg V; Boyett JM; Sinks LF; Jones B; Glicksman A; Holland JF; Freeman AI
Cancer; 1986 Sep; 58(5):1024-8. PubMed ID: 3524797
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
[TBL] [Abstract][Full Text] [Related]
8. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up.
Freeman AI; Boyett JM; Glicksman AS; Brecher ML; Leventhal BG; Sinks LF; Holland JF
Med Pediatr Oncol; 1997 Feb; 28(2):98-107. PubMed ID: 8986145
[TBL] [Abstract][Full Text] [Related]
9. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
[TBL] [Abstract][Full Text] [Related]
10. Acute lymphoblastic leukemia in adults and children. Differences in response with similar therapeutic regimens.
Gee TS; Haghbin M; Dowling MD; Cunningham I; Middleman MP; Clarkson BD
Cancer; 1976 Mar; 37(3):1256-64. PubMed ID: 1063050
[TBL] [Abstract][Full Text] [Related]
11. Intermediate dose methotrexate (IDM) in childhood acute lymphocytic leukemia (ALL).
Freeman AI; Brecher ML; Wang JJ; Sinks LF
Haematol Blood Transfus; 1979; 23():115-23. PubMed ID: 296106
[TBL] [Abstract][Full Text] [Related]
12. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of intensification and maintenance programs in the treatment of acute lymphoblastic leukemia.
Sackmann-Muriel F; Svarch E; Eppinger-Helft M; Braier JL; Pavlovsky S; Guman L; Vergara B; Ponzinibbio C; Failace R; Garay GE; Bugnard E; Ojeda FG; De Bellis R; de Sijvarger SR; Saslavsky J
Cancer; 1978 Oct; 42(4):1730-40. PubMed ID: 101296
[TBL] [Abstract][Full Text] [Related]
14. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia.
Sallan SE; Hitchcock-Bryan S; Gelber R; Cassady JR; Frei E; Nathan DG
Cancer Res; 1983 Nov; 43(11):5601-7. PubMed ID: 6352020
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intermittent or continuous methotrexate plus 6-mercaptopurine in regimens for standard-risk acute lymphoblastic leukemia in childhood (JCCLSG-S811). The Japanese Children's Cancer and Leukemia Study Group.
Koizumi S; Fujimoto T; Takeda T; Yatabe M; Utsumi J; Mimaya J; Ninomiya T; Yanai M
Cancer; 1988 Apr; 61(7):1292-300. PubMed ID: 3278798
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of acute lymphoblastic leukemia in children.
Haghbin M
Am J Hematol; 1976; 1(2):201-9. PubMed ID: 1069475
[TBL] [Abstract][Full Text] [Related]
17. Alternating pulses of vincristine-prednisone with cytarabine-cyclophosphamide versus vincristine-prednisone in the maintenance therapy of acute lymphoblastic leukemia.
Sackmann Muriel F; Svarch E; Pavlovsky S; Bustelo P; Giuntoli J; Vergara B; Garay G; Eppinger-Helft M; Kvicala R; Dibar E
Cancer Treat Rep; 1984 Apr; 68(4):581-6. PubMed ID: 6370428
[TBL] [Abstract][Full Text] [Related]
18. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
[TBL] [Abstract][Full Text] [Related]
19. Teniposide plus cytarabine improves outcome in childhood acute lymphoblastic leukemia presenting with a leukocyte count greater than or equal to 100 x 10(9)/L.
Dahl GV; Rivera GK; Look AT; Hustu HO; Kalwinsky DK; Abromowitch M; Mirro J; Ochs J; Murphy SB; Dodge RK
J Clin Oncol; 1987 Jul; 5(7):1015-21. PubMed ID: 3474355
[TBL] [Abstract][Full Text] [Related]
20. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
